publication date: Jul. 24, 2020

Trials & Tribulations

Assessing the impact of the CMS price transparency rule on patients with prostate cancer

Ankit-Agarwal

Ankit Agarwal, MD, MBA

Resident physician, Department of Radiation Oncology,

University of North Carolina at Chapel Hill

 

Trevor-J.-Royce

Trevor J. Royce, MD, MS, MPH

Assistant professor, Department of Radiation Oncology,

UNC Lineberger Comprehensive Cancer Center,

University of North Carolina at Chapel Hill

 

“It’s the prices, stupid,” Uwe E. Reinhardt and authors famously wrote in their 2003 article describing the cause of high health care spending in the United States.1 Since then, multiple large analyses have confirmed that the prices of labor and goods, including pharmaceuticals and administrative costs, more so than differences in utilization, are the primary drivers of high health care spending.2,3

Although it is well known health care prices are high, it can be difficult for patients and physicians to discern the actual prices of specific health care services.4 This is relevant because the actual negotiated prices can vary substantially (e.g. by over tenfold), even within the same metro area and for the most routine care (e.g. common blood tests).5

Price transparency has been proposed as a potential solution to the high prices of health care by empowering patients to budget for expected costs, apply for financial assistance earlier … Continue reading Assessing the impact of the CMS price transparency rule on patients with prostate cancer

To access this members-only content, please log in.
Institutional subscribers, please log in with your IP.
If you're not a subscriber why not join today?
To gain access to the members only content click here to subscribe.
You will be given immediate access to premium content on the site.
Click here to join.

Copyright (c) 2020 The Cancer Letter Inc.